Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis

Oncogene

Volumn 26, Issue 20, 2007, Pages 2833-2839

  Nilsson, L M ^a,b   Keller, U B ^a   Yang, C ^a   Nilsson, J A ^a,b   Cleveland, J L ^a   Roussel, M F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Arf; Lymphomagenesis; Myc; p18Ink4c

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER MODEL; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE MUTATION; MOUSE; MUTATION RATE; NEWBORN; NONHUMAN; ONCOGENE MYC; PRECANCER; PRIORITY JOURNAL; TRANSGENIC MOUSE; TRANSGENICS; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, IMMUNOGLOBULIN HEAVY CHAIN; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-MYC;

MUS; MUS MUSCULUS;

EID: 34247877676     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210104     Document Type: Article

References (52)

1. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538.
2. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. (1991). Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apopotosis. Oncogene 6: 1915-1922.
3. Bai F, Pei XH, Godfrey VL, Xiong Y. (2003). Haploinsufficiency of p18(INK4c)sensitizes mice to carcinogen-tumorigenesis. Mol Cell Biol 23: 1269-1277.
4. Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A et al. (2003). Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are comprised by E2f1 loss. Mol Cell 11: 905-914.
5. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W et al. (1999). Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 18: 5321-5333.
6. Crews S, Barth R, Hood L, Prehn J, Calame K. (1982). Mouse c-myc oncogene is located on chromosome 15 and translocated to chromosome 12 in plasmacytomas. Science 218: 1319-1321.
7. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. (1982). Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 79: 7824-7827.
8. Damo LA, Snyder PW, Franklin DS. (2005). Tumorigenesis in p27/p53-and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways. Mol Carcinog 42: 109-120.
9. Eischen CM, Rehg JE, Korsmeyer SJ, Cleveland JL. (2002). Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice. Cancer Res 62: 2184-2191.
10. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL. (2001). Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 21: 7653-7662.
11. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658-2669.
12. Eisenman RN. (2001). Deconstructing myc. Genes Dev 15: 2023-2030.
13. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M et al. (1992). Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128.
14. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E et al. (1996). A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85: 733-744.
15. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S et al. (1998). CDK inhibitors p18(INK4c) and p27(Kip1)mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12: 2899-2911.
16. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C et al. (2005). Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 787-789.
17. Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ et al. (2000). Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA 97: 2229-2234.
18. Herold S, Wanzel M, Beuger V, Frohme C, Beul D, Hillukkala T et al. (2002). Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 10: 509-521.
19. Jacobsen KA, Prasad VS, Sidman CL, Osmond DG. (1994). Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of Emu-myc transgenic mice. Blood 84: 2784-2794.
20. Kamijo T, van de Kamp E, Chong MJ, Zindy F, Diehl JA, Sherr CJ et al. (1999). Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res 59: 2464-2469.
21. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA et al. (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659.
22. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES et al. (1996). Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85: 721-732.
23. Knoepfler PS, Cheng PF, Eisenman RN. (2002). N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 16: 2699-2712.
24. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. (2001). Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413: 83-86.
25. Kulkarni MS, Daggett JL, Bender TP, Kuehl WM, Bergsagel PL, Williams ME. (2002). Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia 16: 127-134.
26. Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, Martin-Caballer J et al. (2000). Limited overlapping roles of P15(INK4b)and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 19: 3496-3506.
27. Lowe SW, Sherr CJ. (2003). Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13: 77-83.
28. Maclean KH, Keller UB, Rodriguez-Galindo C, Nilsson JA, Cleveland JL. (2003). c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol 23: 7256-7270.
29. Morishita A, Masaki T, Yoshiji H, Nakai S, Ogi T, Miyauchi Y et al. (2004). Reduced expression of cell cycle regulator p18(INK4C)in human hepatocellular carcinoma. Hepatology 40: 677-686.
30. Morse L, Chen D, Franklin D, Xiong Y, Chen-Kiang S. (1997). Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c)and IL-6. Immunity 6: 47-56.
31. Nilsson JA, Cleveland JL. (2003). Myc pathways provoking cell suicide and cancer. Oncogene 22: 9007-9021.
32. Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA et al. (2005). Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7: 433-444.
33. Nowak NJ, Snijders AM, Conroy J, Albertson DG. (2005). Comparative genomic hybridization. Current Protocols in Human Genetics In: Collins FS (ed). John Wiley & Sons Inc.: New Jersey, pp. 4.1-4.31.
34. Pelengaris S, Khan M, Evan GI. (2002). Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334.
35. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. (1995). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
36. Roussel MF, Cleveland JL, Shurtleff SA, Sherr CJ. (1991). Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signaling. Nature 353: 361-363.
37. Ruas M, Peters G. (1998). The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115-F177.
38. Sanchez-Aguilera A, Delgado J, Camacho FI, Sanchez-Beato M, Sanchez L, Montalban C et al. (2004). Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood 103: 2351-2357.
39. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. (1999). INK4a/ARF mutations acceerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670-2677.
40. Seoane J, Le HV, Massague J. (2002). Myc suppression of the p21(Cip1)Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419: 729-734.
41. Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massague J. (2001). TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol 3: 400-408.
42. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ et al. (2001). Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413: 86-91.
43. Sherr CJ, Roberts JM. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512.
44. Snijders AM, Nowak NJ, Huey B, Fridlyand J, Law S, Conroy J et al. (2005). Mapping segmental and sequence variations among laboratory mice using BAC array CGH. Genome Res 15: 302-311.
45. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H et al. (2001). Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 3: 392-399.
46. Tourigny MR, Ursini-Siegel J, Lee H, Toellner KM, Cunningham AF, Franklin DS et al. (2002). CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity 17: 179-189.
47. Uziel T, Zindy F, Xie S, Lee Y, Forget A, Magdaleno S et al. (2005). The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 19: 2656-2667.
48. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B. (1996). Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J 15: 6595-6604.
49. Wu L, Levine AJ. (1997). Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med 3: 441-451.
50. Wu S, Cetinkaya C, Munoz-Alonso MJ, von der Lehr N, Bahram F, Beuger V et al. (2003). Myc represses differentiation-induced p21CIIP1 expression via Miz-1 dependent interaction with the p21 core promoter. Oncogene 22: 351-360.
51. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z et al. (2001). Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 20: 1688-1702.
52. Zindy F, Nilsson LM, Nguyen L, Meunier C, Smeyne RJ, Rehg JE et al. (2003). Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice. Cancer Res 63: 5420-5427.